Tenderwize
Zurück zur Suche

Open House Discount Agreements for Icatibant

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 217 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Icatibant, ATC B06AC02

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

30 / 100

Risikofaktoren

No estimated value or minimum purchase commitment; revenue uncertainty. Buyer may replace open-house with exclusive con...

Strict proof of marketability required; incomplete documentation may delay or prevent participation.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for Icatibant (ATC B06AC02) medicinal products.
  • Contracts valid from June 2025 to May 2027 with rolling monthly entry.
Vollständige Zusammenfassung anzeigen

This is an Open House (non-exclusive) discount agreement procedure for the active ingredient Icatibant (ATC B06AC02) organized by AOK Rheinland-Pfalz/Saarland. It is not a public procurement under EU Directive 2014/24 but published for transparency. All pharmaceutical companies can join under uniform terms from June 2025 to May 2027, with monthly entry possible. Estimated value is not provided. Only one lot exists. No procurement documents were analyzed, only the notice itself.

Risiken

No estimated value or minimum purchase commitment; revenue uncertainty. Buyer may replace open-house with exclusive con...

Strict proof of marketability required; incomplete documentation may delay or prevent participation.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer) with authorized and marketable medicines in Germany.
  • Medicines must be listed in Lauer-Taxe as marketable or provide proof via AMIce database extracts.
  • Children's medicines (according to BfArM list) are excluded.

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria specified; open-house model with uniform terms for all participants.

Auftraggeber

Lose (1)

LOT-0001

Open House Discount Agreements for Icatibant

Non-exclusive discount agreements for pharmaceutical products containing Icatibant (ATC B06AC02). Contracts last maximum 24 months, ending no later than 31.05.2027. Entry possible on the first of each month. The buyer may replace open-house contracts with exclusive contracts from competitive procedures. Children's medicines according to BfArM list are excluded.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria specified; open-house model with uniform terms for all participants.

Frist

Deadline Mar 31, 2027

Vergabedetails

Veröffentlichungsdatum
10 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
235827-2025

Dokumente (1)

Ähnliche Ausschreibungen